Abstract
A 74-year-old male was found to have pancytopenia with low vitamin B12 levels on routine physical exam with his primary care physician. He complained of increasing fatigue over the last several months, which he attributed to his advancing age, but otherwise felt well. The patient denied any other symptoms. Pertinent family history revealed that his father died of acute leukemia at the age of 66 and his mother died at age 78 with heart complications and possible chronic lymphocytic leukemia. His primary care physician attempted to treat him with vitamin B12 in an effort to address the low levels, but there was no response. For additional assessment of his pancytopenia, the patient was referred to a hematologist who ordered laboratory studies to evaluate his peripheral blood and bone marrow. A complete blood count (CBC) showed megaloblastic anemia, a critically low white blood cell count, and thrombocytopenia. Upon review of the peripheral smear, the pathologist noted moderate anisopoikilocytosis of the red cells and rare circulating blasts. On aspirate smear, an increase in blasts was identified comprising approximately 30% of total nucleated cells. Erythroid precursors were markedly decreased. The core biopsy of the bone marrow correlated with these findings and showed decreased marrow cellularity of approximately 10%. A patchy interstitial increase in blasts was noted, comprising approximately 20% of total nucleated cells. Megakaryocytes were also decreased. Flow cytometric analysis on bone marrow revealed a distinct population of cells, comprising 20% of the total sample which expressed CD13, CD33 (low density), CD34, CD38, CD117, HLA-DR, and CD 45 (low density).
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Gregory T, Wald D, Chen Y et al (2009) Molecular prognostic markers for adult acute myeloid leukemia with normal cytogenetics. J Hematol Oncol 2:23–33
Schnittger S, Schoch C, Kern W et al (2005) Nucleophosmin gene mutations are predictors of favorable prognosis in acute myelogenous leukemia with a normal karyotype. Blood 106:3733–3739
Marcucci G, Mrozek K, Bloomfield C (2005) Molecular heterogeneity and prognostic biomarkers in adults with acute myeloid leukemia and normal cytogenetics. Curr Opin Hematol 12:68–75
Smith-Zagone M, Pulliam J, Farkas D (2006) Molecular pathology methods. In: Leonard D (ed) Molecular pathology in clinical practice. Springer, New York, pp 15–40
Chen W, Rassidakis G, Medeiros L (2006) Nucleophosmin gene mutations in acute myeloid leukemia. Arch Pathol Lab Med 130:1687–1692
Rau R, Brown P (2009) Nucleophosmin (NPM1) mutations in adult and childhood acute myeloid leukaemia: towards definition of a new leukaemia entity. Hematol Oncol 27:171–181
Mrozek K, Heerema N, Bloomfield C (2004) Cytogenetics in acute leukemia. Blood Rev 18:115–136
Arber D, Brunning R, Le Beau M et al (2008) Acute myeloid leukaemia with recurrent genetic abnormalities. In: Swerdlow SH, Campo E, Harris N, Swerdlow SH, Campo E, Harris N et al (eds) WHO classification of tumors of haematopoietic and lymphoid tissues, 4th edn. IARC, Lyon, pp 110–123
Bacher U, Schnittger S, Haferlach C et al (2009) Molecular diagnostics in acute leukemias. Clin Chem Lab Med 47:1333–1341
Leroy H, de Botton S, Grardel-Duflos N et al (2005) Prognostic value of real-time quantitative PCR (RQ-PCR) in AML with t(8;21). Leukemia 19:367–372
Krauter J, Gorlich K, Ottman O et al (2003) Prognostic value of minimal residual disease quantification by real-time reverse transcriptase polymerase chain reaction in patients with core binding factor leukemias. J Clin Oncol 21:4413–4422
Schnittger S, Weisser M, Schoch C et al (2003) New score predicting for prognosis in PML-RARA+, AML1-ETO+, or CBFBMYH11+ acute myeloid leukemia based on quantification of fusion transcripts. Blood 102:2746–2755
Meshinchi S, Alonzo T, Stirewalt D et al (2006) Clinical implications of FLT3 mutations in pediatric AML. Blood 108:3654–3661
Pratz K, Sato T, Murphy K et al (2010) FLT3-mutant allelic burden and clinical status are predictive of response to FLT3 inhibitors in AML. Blood 115:1425–1432
Small D (2006) FLT3 mutations: biology and treatment. Hematology 2006:178–184
Bacher U, Haferlach C, Kern W et al (2008) Prognostic relevance of FLT3-TKD mutations in AML: the combination matters–an analysis of 3082 patients. Blood 111:2527–2537
Falini B, Sportoletti P, Martelli M (2009) Acute myeloid leukemia with mutated NPM1: diagnosis, prognosis and therapeutic perspectives. Curr Opin Oncol 21:573–581
Gulley M, Shea T, Fedoriw Y (2010) Genetic tests to evaluate prognosis and predict therapeutic response in acute myeloid leukemia. J Mol Diagn 12:3–16
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2011 Springer-Verlag Berlin Heidelberg
About this chapter
Cite this chapter
Ramjit, R.T., Hill, C.E. (2011). Acute Myeloid Leukemia: FLT3/NPM1 . In: Schrijver, I. (eds) Diagnostic Molecular Pathology in Practice. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-19677-5_17
Download citation
DOI: https://doi.org/10.1007/978-3-642-19677-5_17
Published:
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-642-19676-8
Online ISBN: 978-3-642-19677-5
eBook Packages: MedicineMedicine (R0)